Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis
Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
The investigators will perform double-blinded placebo-controlled randomized clinical trial
which evaluates the efficacy and safety of allergen-specific intralymphatic immunotherapy
(ILIT) for allergens including Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus
(Dp), cat, and dog that are sensitized and provoke rhinitis-related symptoms in patients with
allergic rhinitis (AR), using allergen extracts for allergen-specific immunotherapy (Tyrosine
S, Allergy Therapeutic, West Sussex, UK).